Covid19, Immunogenicity, Vaccine
Conditions
Keywords
COVID-19, Immunogenicity, Neutralising antibody, Antispike RBD, ChAd0x1 nCoV-19
Brief summary
ChAd0x1 nCoV-19 (AZD 1222) is the main vaccine that is planned to roll-out in Thailand and involve vaccinating people especially in high-risk categories. This vaccine is contained in the multiple-dose vial for vaccinating 10 recipients for 0.5 mL each. However, the additional volume of vaccine was overfilled to 6.5 mL per vial which the vaccination can be administered to more than 10 doses. The University Hospital Network (UHOSNET) and Faculty of Medicine Vajira Hospital, Navamindradhiraj University have jointly stipulated the preparation and vaccination of ChAdox1 - n CoV-19 vaccine with 12 doses per vial injection with traditional 21 or 24 G needle. Taken together, The investigators planned to investigate the immune response of participants after first dose of ChAd0x1 nCoV-19 vaccination with such technique
Detailed description
The investigators measured anti-SARS-CoV-2 antispike RBD IgG and neutralizing antibody by surrogate virus neutralizing test (sVNT) in adults between age 18-72 year after first dose of ChAd0x1 nCoV-19 vaccine.The primary outcome was the antibody levels.The secondary outcome were adverse events,factors affecting antibody levels and incidence of COVID-19 infection at the time of study
Interventions
BIOLOGICALImmunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine
Blood samples were taken from the vaccinated participants for antibody testing against SARS-CoV-2
Sponsors
Bangkok Metropolitan Administration Medical College and Vajira Hospital
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Participants were eligible if they were more than 18 years old.
Exclusion criteria
* Allergic to components of vaccine * Risk of COVID-19 infection in the previous 14 days before enrollment i.e close contact with index cases or history of fever with upper respiratory tract infection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antispike RBD IgG level | Baseline | Level inBAU/ml |
| Neutralizing antibody | Baseline | Percent inhibition |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | through study completion,an average of 1 year | Any abnormal symptoms post vaccination |
| Covid-19 infection | through study completion,an average of 1 year | Incidence of COVID-19 infection |
Countries
Thailand
Outcome results
None listed